Pulmonary Hypertension
Conditions
Sponsors
Sheffield Teaching Hospitals NHS Foundation Trust
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Male over 18, on regular mediciation, unlikely to change Clinical pulmonary hypertension diagnosed 3 months and clinically stable Pulmonary hypertension diagnosed on echocardiography: peak systolic pulmonary artery pressure>50mmg, mean >30mmHg NYHA class II or III Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Unable to perform shuttle test walk or comply with medication Malignancy e.g. breast and prostate Nehrotic syndrome History of primary liver tumours Hypercalcaemia and hypercalciuria Hormone manipulating therapy PSA above th enormal range NYHA class IV Current participation in other research projects
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To evaluate the effect on functional capacity, as defined by an incease in shuttle walk distance, of testosterone supplementation as add on therapy in men with pulmonary hypertension;Secondary Objective: To evaluate the effect on cardiorespiratory, endoparacrine and quality of life parameters of testosterone supplementation as add on therapy in men with pulmonary hypertension;Primary end point(s): Change in functional capacity, as defined by an incease in shuttle walk distance, | — |
Countries
United Kingdom
Outcome results
None listed